trending Market Intelligence /marketintelligence/en/news-insights/trending/Qg9ZVIRq5wV5kdjzlhG_-w2 content esgSubNav
In This List

ANI Pharmaceuticals acquires 23 generic drugs from China's Amerigen for $52.5M

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


ANI Pharmaceuticals acquires 23 generic drugs from China's Amerigen for $52.5M

ANI Pharmaceuticals Inc. acquired 23 generic products from privately held pharmaceutical company Amerigen Pharmaceuticals Ltd. for $52.5 million in cash.

The Baudette, Minn.-based pharmaceutical company, which develops and markets branded and generic medicines in the U.S., will also pay about $25 million to Amerigen over the next four years, ANI said in a Jan. 9 press release.

These payments will be tied to the annual gross profit generated by the acquired portfolio: 10 commercial products, three products with regulatory approval and that are launch-ready, four filed products, four in-development products, and a license to commercialize two approved products, ANI Pharmaceuticals said.